Cas:5774-31-2 2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid manufacturer & supplier

Chemical Name:2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid

CAS.NO:5774-31-2

Synonyms:2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid

Molecular Formula:C₁₆H₁₀N₂O₅

Molecular Weight:310.26100

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:521.5ºC at 760mmHg

Density:1.497g/cm3

Index of Refraction:

PSA:109.15000

Exact Mass:310.05900

LogP:4.12780

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid Use and application,2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid technical grade,usp/ep/jp grade.

Related News: The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace. 2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid manufacturer Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid supplier Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant. 2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid vendor Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high. 2-[2-(5-nitrofuran-2-yl)ethenyl]quinoline-4-carboxylic acid factory The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.